126 related articles for article (PubMed ID: 1577811)
1. A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase.
Black ME; Hruby DE
J Biol Chem; 1992 May; 267(14):9743-8. PubMed ID: 1577811
[TBL] [Abstract][Full Text] [Related]
2. Identification of the ATP-binding domain of vaccinia virus thymidine kinase.
Black ME; Hruby DE
J Biol Chem; 1990 Oct; 265(29):17584-92. PubMed ID: 2211649
[TBL] [Abstract][Full Text] [Related]
3. Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding.
Black ME; Hruby DE
J Biol Chem; 1992 Apr; 267(10):6801-6. PubMed ID: 1551887
[TBL] [Abstract][Full Text] [Related]
4. Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design.
El Omari K; Solaroli N; Karlsson A; Balzarini J; Stammers DK
BMC Struct Biol; 2006 Oct; 6():22. PubMed ID: 17062140
[TBL] [Abstract][Full Text] [Related]
5. Expression and single-step purification of enzymatically active vaccinia virus thymidine kinase containing an engineered oligohistidine domain by immobilized metal affinity chromatography.
Franke CA; Hruby DE
Protein Expr Purif; 1993 Apr; 4(2):101-9. PubMed ID: 8471843
[TBL] [Abstract][Full Text] [Related]
6. Substrate specificity of three viral thymidine kinases (TK): vaccinia virus TK, feline herpesvirus TK, and canine herpesvirus TK.
Solaroli N; Johansson M; Balzarini J; Karlsson A
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1189-92. PubMed ID: 17065088
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance of herpes simplex virus type 1--structural considerations at the molecular level of the thymidine kinase.
Kussmann-Gerber S; Kuonen O; Folkers G; Pilger BD; Scapozza L
Eur J Biochem; 1998 Jul; 255(2):472-81. PubMed ID: 9716390
[TBL] [Abstract][Full Text] [Related]
8. Kinetic studies of the predicted substrate-binding site of varicella-zoster virus thymidine kinase.
Suzutani T; Davies LC; Honess RW
J Gen Virol; 1993 Jun; 74 ( Pt 6)():1011-6. PubMed ID: 8389797
[TBL] [Abstract][Full Text] [Related]
9. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.
Degrève B; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2001 Feb; 59(2):285-93. PubMed ID: 11160865
[TBL] [Abstract][Full Text] [Related]
10. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity.
Kokoris MS; Black ME
Protein Sci; 2002 Sep; 11(9):2267-72. PubMed ID: 12192082
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and crystal structure of the wild-type and the engineered Y101F mutant of Herpes simplex virus type 1 thymidine kinase interacting with (North)-methanocarba-thymidine.
Prota A; Vogt J; Pilger B; Perozzo R; Wurth C; Marquez VE; Russ P; Schulz GE; Folkers G; Scapozza L
Biochemistry; 2000 Aug; 39(31):9597-603. PubMed ID: 10924157
[TBL] [Abstract][Full Text] [Related]
12. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.
Prichard MN; Keith KA; Johnson MP; Harden EA; McBrayer A; Luo M; Qiu S; Chattopadhyay D; Fan X; Torrence PF; Kern ER
Antimicrob Agents Chemother; 2007 May; 51(5):1795-803. PubMed ID: 17325220
[TBL] [Abstract][Full Text] [Related]
13. Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase.
Black ME; Rechtin TM; Drake RR
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1521-7. PubMed ID: 8757995
[TBL] [Abstract][Full Text] [Related]
14. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase.
Balzarini J; Liekens S; Esnouf R; De Clercq E
Biochemistry; 2002 May; 41(20):6517-24. PubMed ID: 12009916
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the recombinant herpes simplex virus type 1 thymidine kinase with thymidine and aciclovir: a kinetic study.
Kussmann-Gerber S; Wurth C; Scapozza L; Pilger BD; Pliska V; Folkers G
Nucleosides Nucleotides; 1999 Mar; 18(3):311-30. PubMed ID: 10358938
[TBL] [Abstract][Full Text] [Related]
16. Expression vector pT7:TKII for the synthesis of authentic biologically active RNA encoding vaccinia virus thymidine kinase.
Wilson EM; Franke CA; Black ME; Hruby DE
Gene; 1989 Apr; 77(1):69-78. PubMed ID: 2744489
[TBL] [Abstract][Full Text] [Related]
17. Biophysical characterization of vaccinia virus thymidine kinase substrate utilization.
Smith RF; Freyer MW; Lewis EA
J Virol Methods; 2007 Jun; 142(1-2):151-8. PubMed ID: 17335913
[TBL] [Abstract][Full Text] [Related]
18. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.
Gustafson EA; Chillemi AC; Sage DR; Fingeroth JD
Antimicrob Agents Chemother; 1998 Nov; 42(11):2923-31. PubMed ID: 9797227
[TBL] [Abstract][Full Text] [Related]
19. Effect of in vitro mutations in a vaccinia virus early promoter region monitored by herpes simplex virus thymidine kinase expression in recombinant vaccinia virus.
Coupar BE; Boyle DB; Both GW
J Gen Virol; 1987 Sep; 68 ( Pt 9)():2299-309. PubMed ID: 2821171
[TBL] [Abstract][Full Text] [Related]
20. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro.
Black ME; Loeb LA
Biochemistry; 1993 Nov; 32(43):11618-26. PubMed ID: 8218229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
